Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | P4HB | P07237 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 5/20 | 0.34 |
| ▸ | ESRRB | O95718 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.33 |
| ▸ | ESRRG | P62508 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460414 | 1.00 | TRPV4 (0.43) | TRPV4KIF11P4HBAPPRAD51 | |
| SCHEMBL170120 | 0.80 | RAD51 (0.37) | KIF11P4HBAPPRAD51 | |
| SCHEMBL2464723 | 0.76 | ALDH1A1 (0.43) | APPRAD51AR | |
| SCHEMBL2886893 | 0.76 | ALDH1A1 (0.43) | APPRAD51AR | |
| SCHEMBL395034 | 0.76 | RAD51 (0.36) | APPRAD51 | |
| SCHEMBL30792697 | 0.76 | TRPV4 (0.53) | TRPV4KIF11P4HBRAD51AR | |
| SCHEMBL395035 | 0.76 | RAD51 (0.36) | APPRAD51 | |
| SCHEMBL1134140 | 0.76 | TRPV4 (0.53) | TRPV4KIF11P4HBRAD51AR | |
| SCHEMBL1738113 | 0.75 | P4HB (0.48) | TRPV4KIF11P4HBAPPRAD51 | |
| SCHEMBL1738112 | 0.75 | P4HB (0.48) | TRPV4KIF11P4HBAPPRAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | QDPR, NQO1, NAT1 | TRPV4 768/4885KIF11 4462/4885P4HB 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.